Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer

Background: S-1 is an oral fluoropyrimidine. This phase II study was designed to evaluate the efficacy and safety of S-1 in patients with advanced or recurrent uterine cervical cancer. Patients and methods: S-1 35 mg/m(2) was given twice daily for 28 days repeated every 6 weeks. Eligible patients we...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsumata, N., Hirai, Y., Kamiura, S., Sugiyama, T., Kokawa, K., Hatae, M., Nishimura, R., Ochiai, K.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101364/
https://www.ncbi.nlm.nih.gov/pubmed/21345941
http://dx.doi.org/10.1093/annonc/mdq602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101364/
https://www.ncbi.nlm.nih.gov/pubmed/21345941
http://dx.doi.org/10.1093/annonc/mdq602

Ejemplares similares